SEP 9, 2026 · JOURNAL ARTICLE
Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers
Advanced Science
Preclinical discovery and optimization study with in vitro, xenograft, and animal toxicology data, but no human clinical evidence; Phase 1 trial is only stated as 'underway' with no results reported.
Reported
Drug-to-Antibody Ratio4